59 unknown, 46 completed, 22 recruiting, 17 not yet recruiting. 53 Not applicable, 24 Phase 2, 17 Phase 1, 6 Phase 3, 6 Phase 4.
Follow Acute-On-Chronic Liver Failure: new trials by email Literature Review of Acute-On-Chronic Liver Failure trials Research Report on Acute-On-Chronic Liver Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial Umbilical cord Mesenchymal stem cell, Steroid, Standard Medical Treatment - Acute-On-Chronic Liver Failure | Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2028-01-01 | 2025-08-17 |
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial ucMSC and Standard medical treatment, Standard medical treatment - Acute-On-Chronic Liver Failure | Phase 2 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2027-01-01 | 2025-08-20 |
| Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) Standard medical therapy (SMT), Double Plasma Molecular Adsorption System (DPMAS) - Acute-on-Chronic Liver Failure (ACLF) | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 56 | 2026-12-15 | 2026-11-06 |
| Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial Vitamin C, Standard of Care (SOC) - Acute-on-Chronic Liver Failure (ACLF) | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 110 | 2026-12-15 | 2026-11-06 |
| A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device. Standard of Care (Investigator Choice), DIALIVE 2.0 liver dialysis Device plus available Standard of Care - Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis | Not applicable | Recruiting | Yaqrit Ltd | 72 | 2026-10-01 | 2026-09-22 |
| RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver) - Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE) | Phase 1 / Phase 2 | Not yet recruiting | eGenesis, INC | 20 | 2026-10-01 | 2026-09-21 |
| Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure NTZ 500mg BID on top of SOC - Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure | Phase 2 | Not yet recruiting | Genfit | 16 | 2026-10-01 | 2026-07-09 |
| Very Low-volume Plasma Exchange in ACLF Double Plasma Molecular Adsorption System (DPMAS), Low-volume plasma exchange, Prothrombin Complex Concentrate (PCC) - Acute on Chronic Liver Failure (ACLF) | Not applicable | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 840 | 2026-10-01 | 2026-10-05 |
| Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis | Not yet recruiting | Assiut University | 100 | 2026-08-01 | 2026-07-29 | |
| Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF DPMAS plus plasma exchange - Acute on Chronic Liver Failure (ACLF) | Not applicable | Not yet recruiting | Unidade Local de Saude do Nordeste | 240 | 2026-07-01 | 2026-05-18 |
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients AS1501 for injection - Acute-On-Chronic Liver Failure | Phase 2 | Recruiting | Shenzhen Third People's Hospital | 96 | 2026-06-15 | 2026-07-17 |
| Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. Midodrine, Standard Medical Treatment - Acute on Chronic Liver Failure | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 113 | 2026-02-05 | 2026-02-20 |
| PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure exosome injection, standard comprehensive internal medical treatment, - Acute-on-Chronic Liver Failure (ACLF) | Early Phase 1 | Active not recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 20 | 2026-01-01 | 2026-02-13 |
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF) umbilical cord Mesenchymal Stem Cell - Acute-On-Chronic Liver Failure | Phase 1 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 10 | 2026-01-01 | 2025-08-28 |
| Risk Factors Affecting MSC Efficacy in ACLF Patients Not applicable- observational study - Acute-On-Chronic Liver Failure | Recruiting | Sun Yat-sen University | 446 | 2025-10-20 | 2025-11-28 | |
| Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers Single Dose G1090N, Multiple dosing of G1090N - Acute-on-Chronic Liver Failure | Phase 1 | Completed | Genfit | 52 | 2025-08-26 | 2026-01-16 |
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| Prognosis of Cirrhotic Patients Admitted to the General Intensive Care Unit Between 2014 and 2024: a Regional Retrospective Multicentre Cohort Study observational study - Cirrhosis, Intensive Care Medicine | Recruiting | Centre Hospitalier Universitaire de Besancon | 500 | 2025-08-08 | 2025-08-11 | |
| Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）, Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）, Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours） - Acute-On-Chronic Liver Failure | Phase 1 | Active not recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 15 | 2025-05-07 | 2025-05-30 |
Showing 20 of 163. Sign in to see all of them.
Liver Cirrhosis (21) · Fibrosis (17) · Hepatitis B (15) · Liver Failure, Acute (14) · Liver Failure (12) · Hepatic Encephalopathy (11) · Liver Diseases (9) · Acute Kidney Injury (5) · End Stage Liver Disease (5) · Sepsis (5) · Hepatitis B, Chronic (4) · Ascites (3) · Hepatitis, Alcoholic (3) · Hepatorenal Syndrome (3)
Digestive System Diseases (163) · Hepatic Insufficiency (163) · Liver Diseases (154) · Liver Failure (151) · Liver Failure, Acute (149) · Pathological Conditions, Signs and Symptoms (50) · Pathologic Processes (49) · Infections (25) · Fibrosis (19) · Hepatitis (19) · Blood-Borne Infections (16) · Communicable Diseases (16) · DNA Virus Infections (16) · Hepadnaviridae Infections (16) · Hepatitis, Viral, Human (16)
Albumins (8) · Plasma Exchange (8) · Lactulose (5) · Tenofovir (5) · Granulocyte Colony-Stimulating Factor (4) · Rifaximin (4) · Terlipressin (4) · Standard of Care (3) · entecavir (3) · Blood Specimen Collection (2) · Carvedilol (2) · Filgrastim (2) · Injections (2) · Meropenem (2) · Midodrine (2)
Institute of Liver and Biliary Sciences, India (39) · Third Affiliated Hospital, Sun Yat-Sen University (13) · Post Graduate Institute of Medical Education and Research, Chandigarh (11) · Nanfang Hospital, Southern Medical University (9) · Genfit (4) · Assiut University (3) · Cellaion SA (3) · European Foundation for Study of Chronic Liver Failure (3) · Hai Li (3) · Qin Ning (3) · RenJi Hospital (3) · Sun Yat-sen University (3) · Yaqrit Ltd (3) · Asian Institute of Gastroenterology, India (2) · Assistance Publique - Hôpitaux de Paris (2)
India (53) · China (45) · Germany (16) · France (14) · Spain (11) · Italy (10) · United Kingdom (10) · Belgium (9) · Austria (7) · United States (7) · Portugal (5) · Poland (4) · Brazil (2) · Bulgaria (2) · Denmark (2)
Liang Peng, Doctor (6) · Dr. Shiv Kumar Sarin, DM (3) · Hai Li (3) · Michael Praktiknjo, MD (2) · Qin Ning, MD., PhD. (2) · Alexander Supady, MD, MPH (1) · Amrish Sahney, MD (1) · Anil Arora, M.D (1) · Antonio Siniscalchi, MD (1) · Arjuna Singanayagam, MBBS; PhD (1) · Banwari Agarwal, Dr (1) · Christine Bernsmeier, PD Dr. Dr. (1)
PMID 31172417, PMID 23474284, PMID 28928275, PMID 32109631, PMID 34412498, PMID 34907041, PMID 35037228, PMID 36052222, PMID 37517452, PMID 42649506, PMID 10898704, PMID 1506645, PMID 16023249, PMID 16684218, PMID 16847391, PMID 17464971, PMID 20335583, PMID 21157444, PMID 21294143, PMID 22119930, PMID 22429562, PMID 22643348, PMID 22873420, PMID 23602141, PMID 23913844, PMID 23993913, PMID 24378272, PMID 24607624, PMID 25715177, PMID 25819304, PMID 26047908, PMID 26084406, PMID 27146801, PMID 27277335, PMID 27339682, PMID 27512927, PMID 27720916, PMID 28223101, PMID 28389120, PMID 28847867, PMID 28902040, PMID 28994123, PMID 29653741, PMID 29729368, PMID 29762630, PMID 29973706, PMID 30345856, PMID 30568347, PMID 30589495, PMID 30905463
2025 (1)